[Evaluation of cochlear and vestibular functions of patients treated by dibekacin in an E.N.T. unit].
Cochlear and vestibular ototoxicity of dibekacin was evaluated in 27 patients treated with aminoglycoside after surgery on head and neck cancer. The treatment was administered intramuscularly or intravenously during 13 days at the schedule of 3 mg/kg per day. Cochlear and vestibular functions were tested by audiometry and electronystagmography before the administration of the antibiotic and on the 14th, 30th day, and for certain patients on the 4th month after the start of the treatment. No cochlear ototoxicity was found after the dibekacin treatment. On the other hand, the dibekacin treatment produced minor abnormalities of ENG (irritative pattern).
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D003051:Cochlea / Q000187:drug effects* / Q000503:physiopathology; D003982:Dibekacin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007759:Labyrinth Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy; D014722:Vestibule, Labyrinth / Q000187:drug effects* / Q000503:physiopathology
D003982:Dibekacin; D007612:Kanamycin
Evaluation des fonctions cochléaires et vestibulaires chez des malades traités par la dibékacine en milieu ORL.